26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
15 November 20213rd SCI-RSC symposium on antimicrobial drug discoveryCoinciding with WHO’s World Antibiotics Awareness week, this two-day meeting will examine the latest advances in antimicrobial drug discovery from…read more >>
25 October 2021BIO-Europe® 2021 Digital – 27th Annual International Partnering ConferenceThe international BIO-Europe® 2021 gathering will be held digitally, providing certainty, in this time of insecurity, to execute its pivotal…read more >>
22 October 2021European Celebration of 5 Years of Progress with CARB-X: A virtual discussion of progress and plans to accelerate innovation globallyA virtual discussion of the critical role that CARB-X and its global partners play in driving the development of innovative…read more >>
21 October 2021REVIVE Webinar: Biofilms: What are they and why do we care?REVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…read more >>
16 October 20215th International Course on Antibiotics and Resistance (ICARe)The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…read more >>
04 October 2021HealthTech Innovation Days in Paris & VirtuallyThe HealthTech Innovation Days drive and foster collaborations within the European healthcare ecosystem. The event features conferences, round tables and private meetings between innovative European…read more >>
20 September 2021BioPharm America™ DigitalBioPharm America™ Digital creates a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage,…read more >>
15 September 2021Johnson & Johnson Innovation – JLABS webinar: Antimicrobial Resistance – Breakthrough Innovation and Breaking BarriersAs multi-drug resistant bacteria become increasingly threatening to global public health and existing antibiotics are becoming ineffective, the global community…read more >>
08 September 2021REVIVE Webinar: Combination antibiotic therapy against drug-resistant Gram-negative bacteria: where the evidence standsREVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…read more >>
